**Table S2**. **No. cases of PCV13- and non-PCV13- type IPD in the different study periods: Anticipated (no PCV13 launch) vs. Observed vs. Expected (PCV13 included in RIP)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **PCV7 period** | **PCV13 period** | **Mixed** | **Private period** |
|  | **2007-08** | **2008-09** | **2009-10** | **2010-11** | **2011-12** | **2012-13** | **2013-14** | **2014-15** |
| **Anticipated**  |  |  |  | 175 [171\_179] | 175 [171\_179] | 175 [171\_179] | 175 [171\_179] | 175 [171\_179] |
| **PCV13-type** |  |  |  | 139 [135\_143] | 139 [135\_143] | 139 [135\_143] | 139 [135\_143] | 139 [135\_143] |
| **Non-PCV13-type** |  |  |  | 43 [42\_44] | 43 [42\_44] | 43 [42\_44] | 43 [42\_44] | 43 [42\_44] |
| **Observed** | 164 [159\_169] | 166 [160\_172] | 170 [164\_176] | 114 [111\_117] | 79 [77\_81] | 54 [52\_56] | 59 [58\_60] | 54 [52\_56] |
| **PCV13-type** | 126 [121\_131] | 133 [128\_138] | 136 [131\_141] | 88 [85\_91] | 45 [43\_47] | 22 [21\_23] | 22 [21\_23] | 9 [8\_10] |
| **Non-PCV13-type** | 38 [37\_39] | 33 [32\_34] | 34 [33\_35] | 26 [25\_27] | 34 [33\_35] | 32 [31\_33] | 37 [36\_38] | 45 [43\_47] |
| **Expected** |  |  |  |  |  | 64 [62\_66] | 58 [56\_60] | 50 [43\_57] |
| **PCV13-type** |  |  |  |  |  | 31 [30\_32] | 16 [16\_16] | 4 [3\_5] |
| **Non-PCV13-type** |  |  |  |  |  | 42 [41\_43] | 42 [41\_43] | 42 [39\_45] |